Editas and Vertex/CRISPR in Gene Editing Race for Sickle Cell Disease and Beta Thalassemia Treatments

The gene editing race between Editas and Vertex, CRISPR heats up as both companies release positive data on their respective gene therapies for sickle cell disease and transfusion-dependent beta thalassemia. Editas unveiled early data from its RUBY and EdiTHAL trials, demonstrating the potential of its gene editor EDIT-301 in treating these diseases. However, Vertex Pharmaceuticals and CRISPR Th..